Mainz Biomed (NASDAQ:MYNZ – Get Free Report) and DEFSEC Technologies (NASDAQ:DFSC – Get Free Report) are both small-cap industrials companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.
Risk and Volatility
Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, DEFSEC Technologies has a beta of 2.82, indicating that its share price is 182% more volatile than the S&P 500.
Valuation and Earnings
This table compares Mainz Biomed and DEFSEC Technologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mainz Biomed | $659,935.00 | 14.14 | -$21.65 million | ($65.60) | -0.02 |
| DEFSEC Technologies | $3.53 million | 0.42 | -$6.88 million | ($4.62) | -0.16 |
DEFSEC Technologies has higher revenue and earnings than Mainz Biomed. DEFSEC Technologies is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Mainz Biomed and DEFSEC Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mainz Biomed | N/A | N/A | N/A |
| DEFSEC Technologies | -120.97% | -144.66% | -82.13% |
Analyst Ratings
This is a breakdown of current ratings for Mainz Biomed and DEFSEC Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mainz Biomed | 1 | 1 | 0 | 0 | 1.50 |
| DEFSEC Technologies | 1 | 0 | 0 | 0 | 1.00 |
Insider & Institutional Ownership
21.4% of DEFSEC Technologies shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Mainz Biomed beats DEFSEC Technologies on 7 of the 12 factors compared between the two stocks.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
About DEFSEC Technologies
DEFSEC develops and commercializes breakthrough next-generation tactical systems for military and security forces. The Company’s current portfolio of offerings includes digitization of tactical forces for real-time shared situational awareness and targeting information from any source (including drones) streamed directly to users’ smart devices and weapons. Other DEFSEC products include countermeasures against threats such as electronic detection, lasers and drones. These systems can operate stand-alone or integrate seamlessly with OEM products and battlefield management systems, and all come integrated with TAK. The Company also has a new proprietary non-lethal product line branded PARA OPSTM with applications across all segments of the non-lethal market, including law enforcement. The Company is headquartered in Ottawa, Canada, with representative offices in London, UK and Abu Dhabi, UAE.
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
